2023-01-01
2023-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:ReblozylMember
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:ReblozylMember
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:ReblozylMember
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:ReblozylMember
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2024-01-01
2024-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2024-01-01
2024-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2024-01-01
2024-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:GardasilGardasil9Member
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2024-01-01
2024-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2024-01-01
2024-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2024-01-01
2024-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2023-01-01
2023-12-31
0000310158
country:US
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
mrk:InternationalMember
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31
0000310158
us-gaap:OperatingSegmentsMember
mrk:ProQuadMMRIIVarivaxMember
mrk:PharmaceuticalsegmentMember
2022-01-01
2022-12-31